mo:re receives 2.3 million euros in seed financing round
The Hamburg-based life science startup mo:re has completed a seed financing round totalling 2.3 million euros. It intends to use the money to accelerate the commercialisation of its laboratory platform, which aims to set new standards in animal-free drug development.
mo:re wants to make animal testing superfluous with its platform
The round is led by High-Tech Gründerfonds (HTGF) with the participation of IFB Innovationsstarter GmbH with the Innovationsstarter Fonds, Gilson Inc, NEDGEX, Nidobirds Ventures and the private investors R&R Medical and Martin Blüggel. They are all investing in a laboratory platform that combines automation and software for planning, conducting and analysing cell culture studies. The use of organoids, organ-like microstructures just a few millimetres in size, is seen as a future replacement for animal testing. Modern organoid models are expected to pave the way to faster drug approval.
mo:re's user-friendly platform aims to simplify the cultivation of cells, make organoids accessible as a standard laboratory technique and deliver verifiable results. The laboratory automation covers all relevant process steps and wants to set a new benchmark for scalability, reproducibility and standardisation of 3D cell culture models. In January, mo:re announced the market launch of its first product at SLAS 2025 in San Diego, the world's leading trade fair for laboratory automation.
